NEW YORK, June 16, 2017 /PRNewswire/ --
On Thursday, June 15, 2017, the NASDAQ Compositeended the trading session at 6,165.50, down 0.47%; the Dow Jones Industrial Average edged 0.07% lower, to finish at 21,359.90; and the S&P 500 closed at 2,432.46, marginally dropping 0.22%. Losses were broad based as six out of nine sectors ended
On Thursday, shares in Boca Raton, Florida headquartered TherapeuticsMD Inc. recorded a trading volume of 1.28 million shares. The stock ended at $4.48, declining 0.44% from the last trading session. The Company's shares have gained 2.05% in the last one month. The stock is trading below its 50-day moving average by 7.67%. Furthermore, shares of TherapeuticsMD, which operates as a women's health care product company, have a Relative Strength Index (RSI) of 53.99. Sign up and read the free research report on TXMD at:
Brentford, the UK headquartered GlaxoSmithKline PLC's stock finished yesterday's session 0.44% lower at $43.43 with a total trading volume of 2.12 million shares. The Company's shares have gained 0.02% in the last one month, 2.77% over the previous three months, and 12.78% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.42% and 5.83%, respectively. Furthermore, shares of GlaxoSmithKline, which engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide, have an RSI of 53.38.
On May 26th, 2017, research firm Berenberg upgraded the Company's stock rating from 'Hold' to 'Buy'. The complimentary research report on GSK can be downloaded at:
At the close of trading on Thursday, shares in Basel, Switzerland headquartered Novartis AG saw a drop of 1.01%, ending the day at $80.45. The stock recorded a trading volume of 1.95 million shares. The Company's shares have advanced 6.32% in the previous three months and 10.45% since the start of this year. The stock is trading 3.01% and 6.76% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Novartis, which researches, develops, manufactures, and markets a range of healthcare products worldwide, have an RSI of 54.04. Register for free on DailyStockTracker.com and access the latest report on NVS at:
New York-based Tonix Pharmaceuticals Holding Corp.'s shares ended the day 4.00% lower at $4.08 with a total trading volume of 106,496 shares. The stock has gained 7.42% over the previous three months. The Company's shares are trading 3.39% below their 50-day moving average. Additionally, shares of Tonix Pharma, which engages in developing pharmaceutical products for central nervous system disorders, have an RSI of 43.96. Get free access to your research report on TNXP at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number:(207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All